Editorial
doi: 10.1111/j.1365-2125.2009.03369.x.
Epub 2009 Jan 21.
Orphan drug development is not taking off
- PMID: 19552743
- PMCID: PMC2686065
- DOI: 10.1111/j.1365-2125.2009.03369.x
Item in Clipboard
Editorial
Orphan drug development is not taking off
Br J Clin Pharmacol.
2009 May.
No abstract available
Similar articles
-
Orphan economics: the downside of supplyside pharmacology.Ann Neurol. 2008 Sep;64(3):A13-6. doi: 10.1002/ana.21432. Ann Neurol. 2008. PMID: 18825669 No abstract available.
-
The Orphan Drug Act: how well is it working?Am Pharm. 1985 Sep;NS25(9):52-4. doi: 10.1016/s0160-3450(16)32834-3. Am Pharm. 1985. PMID: 4050674 No abstract available.
-
March on, not in.Nat Med. 2011 May;17(5):515. doi: 10.1038/nm0511-515. Nat Med. 2011. PMID: 21546944 No abstract available.
-
Can lifecycle management safeguard innovation in the pharmaceutical industry?Drug Discov Today. 2018 Dec;23(12):1962-1973. doi: 10.1016/j.drudis.2018.10.008. Epub 2018 Oct 17. Drug Discov Today. 2018. PMID: 30342247 Review.
-
[Orphan drugs from the perspective of research-based pharmaceutical and biotech companies].Internist (Berl). 2019 Apr;60(4):405-410. doi: 10.1007/s00108-019-0579-6. Internist (Berl). 2019. PMID: 30859276 Review. German. No abstract available.
Cited by
-
Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.Pharmacoeconomics. 2011 Jan;29(1):63-82. doi: 10.2165/11539190-000000000-00000. Pharmacoeconomics. 2011. PMID: 21073206
-
The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging.Eur J Drug Metab Pharmacokinet. 2021 Sep;46(5):575-593. doi: 10.1007/s13318-021-00700-5. Epub 2021 Jul 21. Eur J Drug Metab Pharmacokinet. 2021. PMID: 34287806 Free PMC article. Review.
-
Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?Orphanet J Rare Dis. 2011 Sep 5;6:59. doi: 10.1186/1750-1172-6-59. Orphanet J Rare Dis. 2011. PMID: 21892964 Free PMC article.
-
Navigating challenges and opportunities in orphan medicines: A spotlight commentary on rare diseases.Br J Clin Pharmacol. 2025 Apr;91(4):1084-1087. doi: 10.1002/bcp.70013. Epub 2025 Feb 16. Br J Clin Pharmacol. 2025. PMID: 39956537 Free PMC article. No abstract available.
-
Delays in the submission of new drugs in Canada.CMAJ. 2015 Jan 6;187(1):E47-E51. doi: 10.1503/cmaj.130814. Epub 2014 May 12. CMAJ. 2015. PMID: 24821865 Free PMC article. Review. No abstract available.
References
-
- Schieppati A, Henter J-I, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet. 2008;371:2039–41. - PubMed
-
- Remuzzi G, Garattini S. Rare diseases: what's next? Lancet. 2008;371:1978–9. - PubMed
-
- Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities. L18:1–5. 22.01.2000.
-
- Committee for Proprietary Medicinal Products. Note for Guidance on Repeated Dose Toxicity. [accessed 21 March 2008]. July 2000. Available at http://www.emea.europa.eu/pdfs/human/swp/104299en.pdf.
-
- Committee for Proprietary Medicinal Products. Note for guidance on duration of chronic toxicity testing in animals (rodent and non rodent toxicity testing) [accessed 26 November 2008]. May 1999. Available at http://www.emea.europa.eu/pdfs/human/ich/030095en.pdf.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
